{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T08:40:02Z","timestamp":1750754402748,"version":"3.41.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study compares toxicity and oncologic outcomes in a matched cohort of soft tissue sarcoma (STS) patients receiving ultra-hypofractionated preoperative radiation therapy (RT) or standard fractionated RT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This IRB-approved study included patients with STS of the extremity, pelvis, or trunk treated with preoperative RT followed by surgical resection. Patients received either standard RT or ultra-hypofractionated RT (\u226530 Gy over 5 fractions) between 2016 and 2023 with intensity-modulated RT\ufeff at a single institution. Ultra-hypofractionated RT patients proceeded to surgical resection 0 to 7 days after RT and standard fractionated RT group 4 to 6 weeks after completion. The cohorts were matched based on tumor location and type of surgical closure. An inverse propensity weighting (IPW) method was used to balance group covariates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 74 patients were included in this study. 37 patients treated with ultra-hypofractionated RT were matched with 37 patients treated with standard fractionation RT. Median follow-up time was 21.00 [IQR 11.00, 45.00] months for ultra-hypofractionated RT and 29.00 [IQR 13.00, 43.00] months for standard fractionated RT (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.58). Rates of major wound complications (MWC) were 44.4% ultra-hypofractionated RT versus 29.7% standard RT (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.289). On logistic regression, MWC (OR 1.9, 95% CI 0.97-3.76, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.06) and wound dehiscence (OR 3.91, 95% CI 1.81-8.73, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.0006) were more common in the ultra-hypofractionated RT group. Clinically significant late toxicity (grade \u22652 fibrosis, joint stiffness, or edema) did not differ significantly. \ufeffThere was no difference in local control (<jats:italic toggle=\"yes\">P<\/jats:italic>=1.00) or distant metastases (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.465).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Ultra-hypofractionated RT for STS results in excellent disease control. To reduce the risk of MWC, we have adopted delayed surgical resection for ultra-hypofractionated RT patients of 4 to 6 weeks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000001185","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T06:00:17Z","timestamp":1742364017000},"page":"345-350","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Matched Cohort Analysis of Ultra-hypofractionated Versus Standard Fractionation Preoperative Radiation Therapy for Soft Tissue Sarcoma"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7728-9264","authenticated-orcid":false,"given":"Cong","family":"Fan","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Nystrom","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan W.","family":"Mesko","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary D.","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary S.","family":"Mayo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag S.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomo A.","family":"Koyfman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic"},{"name":"Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-0294","authenticated-orcid":false,"given":"Shauna R.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"R2-20250624","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O\u2019Sullivan","year":"2002","journal-title":"The Lancet"},{"key":"R3-20250624","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.020","article-title":"Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma","volume":"75","author":"Davis","year":"2005","journal-title":"Radiother Oncol"},{"key":"R4-20250624","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpra.2017.04.001","article-title":"Impaired wound healing after radiation therapy: a systematic review of pathogenesis and treatment","volume":"13","author":"Jacobson","year":"2017","journal-title":"JPRAS Open"},{"key":"R5-20250624","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1748-717X-7-162","article-title":"Wound healing after radiation therapy: review of the literature","volume":"7","author":"Haubner","year":"2012","journal-title":"Radiat Oncol"},{"key":"R6-20250624","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prro.2021.04.005","article-title":"Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO Clinical Practice Guideline","volume":"11","author":"Salerno","year":"2021","journal-title":"Practical Radiat Oncol"},{"key":"R7-20250624","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prro.2020.08.004","article-title":"Radiation therapy for rectal cancer: executive summary of an ASTRO Clinical Practice Guideline","volume":"11","author":"Wo","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"R8-20250624","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-20250624","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","author":"Erlandsson","year":"2017","journal-title":"Lancet Oncol"},{"key":"R10-20250624","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13014-022-02072-9","article-title":"Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review","volume":"17","author":"Roohani","year":"2022","journal-title":"Radiat Oncol"},{"key":"R11-20250624","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canrad.2022.07.014","article-title":"Preoperative ultra-hypofractionation radiotherapy in extremity\/trunk wall soft tissue sarcoma\u2014a meta-analysis of prospective studies","volume":"27","author":"Kao","year":"2023","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"R12-20250624","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2021.06.027","article-title":"Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities","volume":"161","author":"Leite","year":"2021","journal-title":"Radiother Oncol"},{"key":"R13-20250624","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.radonc.2021.03.033","article-title":"Neoadjuvant hypofractionated radiotherapy and chemotherapy for extremity soft tissue sarcomas: Safety, feasibility, and early oncologic outcomes of a phase 2 trial","volume":"159","author":"Gobo Silva","year":"2021","journal-title":"Radiother Oncol"},{"key":"R14-20250624","doi-asserted-by":"crossref","first-page":"100850","DOI":"10.1016\/j.adro.2021.100850","article-title":"Is 5 the new 25? Long-term oncologic outcomes from a phase II, prospective, 5-fraction preoperative radiation therapy trial in patients with localized soft tissue sarcoma","volume":"7","author":"Bedi","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"R15-20250624","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1078-0432.CCR-19-3524","article-title":"A phase II trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma","volume":"26","author":"Kalbasi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R16-20250624","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijrobp.2021.02.019","article-title":"Combined preoperative hypofractionated radiotherapy with doxorubicin-ifosfamide chemotherapy in marginally resectable soft tissue sarcomas: results of a phase 2 clinical trial","volume":"110","author":"Spa\u0142ek","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-20250624","doi-asserted-by":"crossref","first-page":"109439","DOI":"10.1016\/j.radonc.2022.109439","article-title":"Early outcomes of ultra-hypofractionated preoperative radiation therapy for soft tissue sarcoma followed by immediate surgical resection","volume":"180","author":"Mayo","year":"2023","journal-title":"Radiother Oncol"},{"key":"R18-20250624","doi-asserted-by":"crossref","first-page":"e205865","DOI":"10.1001\/jamaoncol.2020.5865","article-title":"Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial","volume":"7","author":"Lansu","year":"2021","journal-title":"JAMA Oncol"},{"key":"R19-20250624","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2014.58.5828","volume":"33","author":"Wang","year":"2015","journal-title":"J Clin Oncol"},{"key":"R20-20250624","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.3390\/cancers13122981","article-title":"Efficacy and safety of hypofractionated preoperative radiotherapy for primary locally advanced soft tissue sarcomas of limbs or trunk wall","volume":"13","author":"Kose\u0142a-Paterczyk","year":"2021","journal-title":"Cancers"},{"key":"R21-20250624","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.adro.2020.06.024","article-title":"Early outcomes of preoperative 5-fraction radiation therapy for soft tissue sarcoma followed by immediate surgical resection","volume":"5","author":"Parsai","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"R22-20250624","doi-asserted-by":"crossref","first-page":"101165","DOI":"10.1016\/j.tranon.2021.101165","article-title":"Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization","volume":"14","author":"Yang","year":"2021","journal-title":"Transl Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T08:00:28Z","timestamp":1750752028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001185","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"type":"print","value":"0277-3732"},{"type":"electronic","value":"1537-453X"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}